Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : 4D-175
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : 4D Molecular Therapeutics
Deal Size : $140.0 million
Deal Type : Agreement
Details : Under the agreement, Aevitas’ transgene encoding sCFH, a shortened and optimized form of a natural inhibitor of the inflammatory complement pathway, will be combined with 4DMT’s proprietary retinotropic R100 vector to form 4D-175 for treatment of GA ...
Product Name : 4D-175
Product Type : Cell and Gene therapy
Upfront Cash : $140.0 million
April 24, 2023
Lead Product(s) : 4D-175
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : 4D Molecular Therapeutics
Deal Size : $140.0 million
Deal Type : Agreement
Reset All
